Clostridium Difficile Clinical Trial
Official title:
A Feasibility Randomized Trial of Intestinal Lavage for the Treatment of Severe C. Difficile Infections
Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and
supportive care, with surgical intervention reserved for patients with significant systemic
toxicity or perforation. Severe CDI may be refractory to medical management and require
surgical intervention, carrying a mortality of approximately 40%.
Mortality associated with CDI increases significantly as the severity of the infection
increases. In patients failing medical management, earlier operation is associated with
decreased mortality. However, the lack of validated tools to predict the necessity for
surgical intervention, combined with the significant morbidity associated with total
colectomy significantly reduces the likelihood of patients receiving early surgical
intervention. The purpose of the proposed study is to assess the addition of intestinal PEG
lavage via nasojejunal tube to usual care in the treatment of adult patients with severe CDI
who have no immediate indication for surgical intervention.
Despite a lack of definitive evidence, total abdominal colectomy (TAC) is currently
recommended as the surgical intervention of choice in the setting of severe-complicated CDI.
This recommendation was based on meta-analysis of studies comparing TAC to partial colectomy
or other surgery (such as exploratory laparotomy without colectomy, or ostomy formation) or
no surgery, which did not find any statistical mortality difference. This recommendation is
based on the results of sensitivity analysis and an expert panel consensus that considered
the potential for confounding factors such as TAC occurring later in the course of the
disease and on sicker patients, and on anticipated patient values that would pace value on a
definitive procedure being the initial surgical intervention.
Given the high mortality of fulminant CDI, early surgical intervention is recommended.
However, data regarding the optimal timing for surgical intervention is lacking.
Meta-analyses and guidelines strongly recommend early surgical management, defined as being
before the development of shock or the requirement for vasopressors, based on very low
quality evidence, but with the potential for significant mortality reduction.
On the basis of CDI being a toxin mediated inflammatory process of the colonic mucosa, Neal
et al hypothesized that surgical diversion of the fecal stream with a loop ileostomy and
intraoperative antegrade colonic lavage may effectively treat severe CDI. Widely referred to
as the 'Pittsburgh Protocol,' the regimen included colonic lavage with 8 litres of
polyethylene glycol (PEG 3350) intra-operatively after formation of a loop ileostomy,
followed by antegrade Vancomycin flushes (500mg in 500cc Ringer's Lactate TID) and IV
Metronidazole (500mg TID) for 10 days. The study utilized a before-and-after methodology
comparing the experimental protocol to historical controls. Forty-two patients were submitted
to the regimen over 18 months. Three patients required reoperation for TAC. 30-day mortality
was 19% in the intervention cohort, compared to 50% in the control. 79% of survivors went on
to ileostomy reversal within 6 months of surgery. One of the potential benefits of this
regimen is that given the reduced morbidity compared to TAC, practitioners may have been
offering surgical intervention earlier in the management of CDI and not exclusively as a
therapy of last resort. Despite the limited sample size and methodological shortcoming of
this study, this treatment regime has been adopted in some centres for select cases. A
randomized controlled trial to compare this less invasive surgical approach with total
abdominal colectomy was closed prematurely given lack of meaningful patient enrolment
(clinicaltrials.gov identifier NCT01441271).
Given the positive results of fecal diversion and antegrade lavage and vancomycin flushed
proposed by Neal et al, combined with the limited data regarding the benefit of intracolonic
vancomycin, a novel treatment was instituted at London Health Sciences Centre (LHSC) to
accomplish lavage of the colon and vancomycin flushes in an antegrade fashion using a
nasojejunal feeding tube to facilitate delivery in select patients. The protocol allows for
lavage and intracolonic antibiotic delivery similar to that provided by the 'Pittsburgh
protocol' without surgical fecal diversion.
A small preliminary cohort of patients completing this protocol at LHSC is being assessed
retrospectively, comparing outcomes to a group undergoing the Pittsburgh protocol and initial
total colectomy. The study was approved by the Western University Research Ethics Board (REB
File # 104944). Interim analysis of the past 24 months includes 13 patients undergoing the
study protocol, 9 undergoing the Pittsburgh protocol and 17 undergoing initial colectomy.
Despite significant limitations of the study methodology, the results are encouraging and
further study is warranted, especially given the significant mortality associated with
fulminant CDI.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02896244 -
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
|
||
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Recruiting |
NCT01973465 -
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
|
N/A | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT01066221 -
Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile
|
N/A | |
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
Completed |
NCT02857582 -
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
|
Phase 2 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT01703494 -
Fecal Transplant for Relapsing C. Difficile Infection
|
Phase 2 | |
Completed |
NCT01813500 -
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01087892 -
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection
|
N/A | |
Suspended |
NCT00591357 -
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
|
Phase 4 | |
Recruiting |
NCT00377078 -
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
|
N/A | |
Completed |
NCT02254967 -
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
|
Phase 4 | |
Terminated |
NCT01775397 -
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
|
Phase 4 | |
Terminated |
NCT03617172 -
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
|
Phase 2 | |
Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
Completed |
NCT02437487 -
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
|
Phase 2 |